Wu was vice president of business development at Genelabs Technologies Inc., where he was responsible for all business development and licensing activities, including search, evaluation, contract negotiations for all in- and out-license transactions as well as alliance management and assisting in corporate financing activities. At Genelabs, Wu completed numerous licensing agreements and research collaborations with companies including Novartis, Gilead and Affymetrix.
Prior to Genelabs, Wu participated in the 1997 establishment of Kissei Pharma, the U.S. subsidiary of Kissei Pharmaceuticals Co. of Japan. Wu also was director of business development for Quintiles-BRI, a clinical research organization, after working for 16 years at Syntex Corporation. At Syntex, he held numerous positions with increasing responsibility, beginning as a chemist at the Syntex Research Institute of Pharmaceutical Sciences and culminating as director of R&D Program Planning and Management for the company's Japanese subsidiary.
Wu received his MBA in International Finance from the University of San Francisco, School of Business. He has been a member of the American Association of Pharmaceutical Scientist Planning Committee for Harmonization of Pharmaceutical Science Requirements, the New York Pharma Forum, the Japan Society of Northern California, the Healthcare Study Group (JETRO New York), the Regulatory Affairs Professional Society, and the Licensing Executive Society and Drug Information Association. Wu has been a frequent speaker at conferences including the Bay Bio Panel, Hepatitis C in Search of a Cure, Conducting Clinical Trials in Japan, Pacific Rim Biotech Conference and BIO.
NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide(R) compounds, which are novel, synthetic anti-infective product candidates that are
Page: 1 2 3 Related biology technology :1
|SOURCE NovaBay Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference2
. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results3
. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States4
. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients5
. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights6
. Brookstone Pharmaceuticals Appoints New Corporate Position7
. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets8
. Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results9
. Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors10
. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 411
. BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009